Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Arch Dermatol Res ; 316(6): 336, 2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38844670

RÉSUMÉ

Telogen effluvium is characterized by excessive hair shedding usually following a stressful event. Ferritin has been used in clinical practice as a biomarker of nonanemic iron deficiency in cases of telogen effluvium. During the years of the COVID19 pandemic, telogen effluvium was reported as a part of post covid manifestations. As ferritin was also a biomarker for inflammation in cases with covid infection, this study was designed to evaluate the value of ferritin in cases with postcovid telogen effluvium one hundred patients recovering from covid 19 for 4-12 weeks were included in the study, detailed drug and laboratory history was obtained and serum ferritin level was measured. the mean serum level of ferritin among telogen effluvium patients was significantly lower than controls (68.52 ± 126 and 137 ± 137.597 ug/L respectively). Patients with telogen effluvium used significantly more azithromycin and ivermectin and significantly less vitamin C, D, lactoferrin and zinc than the controls Although serum ferritin is lower among telogen effluvium patients, it was still higher than the cutoff value for diagnosing nonanemic iron deficiency, we suggest that it will not be a good biomarkers in these cases. Our secondary outcomes showed that dietary supplements used during active infection such as vitamin C, D, lactoferrin and zinc might have a preventive value on postcovid hair loss, while azithromycin and ivermectin could have a negative long term effect on telogen effluvium.


Sujet(s)
Marqueurs biologiques , COVID-19 , Compléments alimentaires , Ferritines , Humains , Ferritines/sang , COVID-19/sang , COVID-19/diagnostic , Marqueurs biologiques/sang , Femelle , Adulte , Mâle , Études cas-témoins , Adulte d'âge moyen , SARS-CoV-2 , Azithromycine/usage thérapeutique , Ivermectine/usage thérapeutique , Alopécie/diagnostic , Alopécie/sang , Alopécie/étiologie , Poils , Jeune adulte
2.
Arch Dermatol Res ; 316(7): 359, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38850412

RÉSUMÉ

Post-acne erythema (PAE) is a bothering skin condition that emerges from inflammatory acne and persists after its resolution. It is characterized by telangiectasia and erythematous macules. the role of 1064-nm Nd: YAG when combined with low-dose isotretinoin in the acne erythema treatment. forty-eight PAE patients were involved in the study. They were divided into two groups; group (A) patients administering a low dose of oral isotretinoin (10 mg/day) and underwent a total of six two-week interval sessions of 1064 ND-YAG laser treatment, group (B) patients administering a low dose of oral isotretinoin (10 mg/day) only. All adverse effects experienced during the course of therapy were documented, and photos were taken before the start of the treatment and following the end of the treatment duration. Following the completion of the therapeutic intervention, a significant improvement in clinical condition was observed in both groups, with more improvement in group (A) compared to group (B) as evidenced by a notable improvement in the score on the Clinician Erythema Assessment Scale (CEAS) and also a significant decrease in the mean value of optical density of the erythema. combined 1064-nm Nd: YAG with low-dose isotretinoin may be an efficient and secure line in the PAE treatment. Also, the combined therapy had superior results when compared to low-dose isotretinoin alone.


Sujet(s)
Acné juvénile , Produits dermatologiques , Érythème , Isotrétinoïne , Lasers à solide , Humains , Isotrétinoïne/administration et posologie , Isotrétinoïne/effets indésirables , Isotrétinoïne/usage thérapeutique , Érythème/étiologie , Érythème/diagnostic , Érythème/traitement médicamenteux , Acné juvénile/traitement médicamenteux , Acné juvénile/thérapie , Acné juvénile/diagnostic , Femelle , Mâle , Lasers à solide/usage thérapeutique , Lasers à solide/effets indésirables , Adulte , Produits dermatologiques/administration et posologie , Produits dermatologiques/effets indésirables , Jeune adulte , Résultat thérapeutique , Adolescent , Association thérapeutique/méthodes , Association thérapeutique/effets indésirables
3.
J Cosmet Dermatol ; 21(11): 6209-6214, 2022 Nov.
Article de Anglais | MEDLINE | ID: mdl-35780292

RÉSUMÉ

BACKGROUND: Acne vulgaris (AV) is a complex and multifactorial inflammatory disease affecting the pilosebaceous follicles. Optimum treatment of AV is important to reduce the disease severity and recurrence. AIM: To evaluate the role of metformin in the treatment of acne vulgaris by reducing the level of insulin-like growth factor 1. METHODS: Fifty patients with AV were included in the study. Their ages ranged from 16 to 30 years, and they had different grades of the disease. IGF-1 levels were measured in all patients before and after the treatment with metformin. RESULTS: After 4 months of therapy, there was a clinical improvement detected by an improvement in the global acne grading system (GAGS) score and also a significant decrease in IGF-level. CONCLUSION: IGF-1 may have an important role in the pathogenesis of acne; also we can presume that oral metformin is an effective and safe line in the treatment of AV.


Sujet(s)
Acné juvénile , Metformine , Humains , Adolescent , Jeune adulte , Adulte , Facteur de croissance IGF-I/métabolisme , Metformine/usage thérapeutique , Acné juvénile/étiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE